ScreenerHero

IBRX ImmunityBio, Inc.

NAS · US · Healthcare · Biotechnology · immunitybio.com
9.750USD+0.62%Mkt Cap: 10.33B $P/E: —

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap10.33B USD
Enterprise Value11.14B USD
Revenue (TTM)165.79M USD
Gross Profit112.53M USD
Net Income (TTM)-351.40M USD
Revenue/Share0.17 USD
Last Price9.750 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees684
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-69.21
PEG—
EV/EBITDA-47.35
EV/Revenue67.20
P/S61.94
P/B-9.75
EPS (TTM)-0.96
EPS (Forward)-0.14
52W Range
1.95074% of range12.43
52W High12.43 USD
52W Low1.950 USD
Profitability
Gross Margin99.34%
Oper. Margin-120.41%
EBITDA Margin-141.92%
Profit Margin-310.18%
ROE70.21%
ROA-70.01%
Growth
Revenue Growth93.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-304.94M USD
CapEx (TTM)4.25M USD
FCF Margin-112.53%
FCF Yield-1.81%
Net Debt871.03M USD
Net Debt/EBITDA-3.70
Balance Sheet
Debt/Equity-1.04
Current Ratio5.72
Quick Ratio5.36
Book Value/Sh-0.99 USD
Cash/Share0.34 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.75 USD
Upside (mean)+30.8%
Target Range12.00 USD – 15.00 USD
12.00+30.8% to mean15.00
# Analysts4
Ownership
Shares Out.1.06B
Float406.64M
Insiders62.17%
Institutions19.78%
Short Interest
Short Ratio15.1d
Short % Float31.28%
Short % Out.11.83%
Shares Short125.41M
Short (prev mo.)127.50M
Technical
SMA 508.064 (+20.9%)
SMA 2007.246 (+34.5%)
Beta0.03
S&P 52W Chg16.45%
Avg Vol (30d)11.48M
Avg Vol (10d)15.64M
Technical Indicators
RSI (14)61.2
MACD0.5147
MACD Signal0.4000
MACD Hist.+0.1147
BB Upper10.36 USD
BB Middle8.830 USD
BB Lower7.299 USD
BB Width34.68%
ATR (14)0.6153 USD
Vol Ratio (20d)0.89x